Breda Barbič-Žagar
Publications by Year
Research Areas
Blood Pressure and Hypertension Studies, Lipoproteins and Cardiovascular Health, Hormonal Regulation and Hypertension, Heart Rate Variability and Autonomic Control, Cardiac, Anesthesia and Surgical Outcomes
Most-Cited Works
- → Survival and event-free survival of patients with peripheral arterial disease undergoing prevention of cardiovascular disease(2017)21 cited
- → The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension — the VICTORY trial(2016)9 cited
- Prevention of ischemic events in patients with peripheral arterial disease design, baseline characteristics and 2-year results an observational study.(2011)
- → Achieving Blood Pressure Control with Telmisartan and Fixed Dose Combination of Telmisartan and Hydrochlorothiazide(2016)4 cited
- → [PP.26.07] IMPACT OF VALSARTAN AND COMBINATION OF VALSARTAN AND HYDROCHLOROTHIAZIDE ON ERECTILE DYSFUNCTION IN PATIENTS WITH MILD TO MODERATE HYPERTENSION(2016)3 cited
- → The influence of antyhypertensive therapy of valsartan and fixed combination with hydrochlorothiazide use on pulse-wave velocity and central arterial pressure in patients with arterial hypertension of 1-2 grades in international VICTORY clinical trial(2018)2 cited
- → The results of the international clinical study VICTORY: efficacy and safety of antihypertensive monotherapy with valsartan (Valsacor®) and its fixed combination with hydrochlorothiazide (Valsacor® H) in routine clinical practice in patients with grade 1 and grade 2 hypertension(2017)2 cited
- → Krka’s Added-value Generic Medications(2019)2 cited
- → The Efficacy and Safety of Single-pill Combination of Amlodipine/valsartan (Wamlox®) and Amlodipine/valsartan/hydrochlorothiazide (Valtricom®) in Patients with Grade 2 or 3 Arterial Hypertension – the VICTORY II Study(2020)2 cited
- → High-quality Valsartans Contributing to the Treatment of Hypertension and Beyond for More than 15 Years(2022)1 cited